Kapitalo Investimentos Ltda Invests $808,000 in Catalent, Inc. (NYSE:CTLT)

Kapitalo Investimentos Ltda bought a new position in Catalent, Inc. (NYSE:CTLT) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 13,348 shares of the company’s stock, valued at approximately $808,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Creative Planning grew its position in Catalent by 21.4% in the 3rd quarter. Creative Planning now owns 6,935 shares of the company’s stock valued at $420,000 after acquiring an additional 1,222 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its position in Catalent by 57.5% in the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock valued at $72,000 after acquiring an additional 431 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt grew its position in Catalent by 1,400.0% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,500 shares of the company’s stock valued at $91,000 after acquiring an additional 1,400 shares during the last quarter. Contravisory Investment Management Inc. grew its position in Catalent by 1,329.9% in the 3rd quarter. Contravisory Investment Management Inc. now owns 130,878 shares of the company’s stock valued at $7,927,000 after acquiring an additional 121,725 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Catalent by 26.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock valued at $79,000 after acquiring an additional 278 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have commented on CTLT. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. StockNews.com started coverage on Catalent in a research report on Saturday. They issued a “hold” rating on the stock. Barclays upped their target price on Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, June 28th. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. Nine investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $59.83.

Catalent Price Performance

CTLT opened at $60.66 on Wednesday. The firm has a market capitalization of $10.98 billion, a PE ratio of -9.94, a price-to-earnings-growth ratio of 2.14 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. The business’s 50-day moving average is $60.06 and its two-hundred day moving average is $57.68. Catalent, Inc. has a 1 year low of $31.80 and a 1 year high of $61.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The firm had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.23 billion. Research analysts anticipate that Catalent, Inc. will post 0.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares of the company’s stock, valued at $10,431,133.96. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,410 shares of company stock valued at $732,680. 0.31% of the stock is currently owned by insiders.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.